Anonymizing and combining past clinical, genetic, and imaging data from people with multiple myeloma to build AI prediction models.
Official title: Anonymization of Clinical Data From Pseudonymized Databases Collected as Part of Previus Clinical Trials on Multiple Myeloma
Run by IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT07283224 · Data updated 2026-11-12
This project will try to use already-collected clinical, genetic, and imaging data from adults with multiple myeloma to build AI models that predict disease progression and treatment response, with no new visits or tests required.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 600 (estimated) |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna Academic / other |
| Locations | 1 site (Bologna, Bo) |
| Status | Recruiting |
| Started | June 30, 2025 |
| Main results expected | January 1, 2027 |
| Study ends | January 1, 2028 |
| Registry record updated | May 12, 2026 |
| Trial ID | NCT07283224 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (age ≥18) with a confirmed diagnosis of multiple myeloma who were previously enrolled in spontaneous trials at the Hematology Unit, IRCCS AOU di Bologna and for whom pseudonymized datasets are already available.
✕Probably not a fit
Patients who were not previously enrolled at this center, whose records are missing or low-quality, or whose data cannot be anonymized will not be included and will not receive any direct benefit from this retrospective work.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a retrospective, single-center observational project that integrates pseudonymized clinical, genomic, and imaging data previously collected at the Hematology Unit of IRCCS AOU di Bologna. The team will anonymize existing datasets and apply machine learning and artificial intelligence methods to link genetic, clinical, and imaging features with disease outcomes. No new procedures, tests, or patient visits are required because all analyses use past data from spontaneous trials beginning in 2021. The goal is to create predictive models that could help forecast progression and treatment response in future patients.
Why it matters
Potential benefit: If successful, the resulting models could help identify patients at higher risk of progression and guide more personalized treatment decisions in the future.
How similar studies have gone: Previous research using machine learning on genomic and clinical data in multiple myeloma has shown promising preliminary results but remains exploratory and not yet practice-changing.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥18 years * Signed Informed Consent * Patients with confirmed diagnosis of MM, previously enrolled in spontaneous trial conducted at the UOC Ematologia, IRCCS AOU di Bologna, from 2021, for whom pseudonymized datasets are already available at the start of this study. Exclusion Criteria: * None
Where it's running
-
IRCCS AOU Policlinico Sant'Orsola
Bologna, Bo, Italy Recruiting
Study contacts
- Study coordinator: Carolina Terragna, MD
- Email: carolina.terragna@unibo.it
- Phone: 0512143831
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
BCD-248 plus daratumumab in relapsed or refractory multiple myeloma
This study tests whether adding BCD-248 to daratumumab helps people with relapsed or refractory multiple myeloma who have had prior lines of therapy.
-
Immune Fitness in Older Adults with Relapsed or Refractory Multiple Myeloma
This study checks whether immune health before treatment can predict how well older adults with relapsed or refractory multiple myeloma respond to CAR-T or bispecific antibody therapies.
-
Infectious complications in blood cancer patients treated with bispecific antibodies
This study tests how often infections occur in adults with blood cancers who are being treated with bispecific antibodies.
-
Mapping individual multiple myeloma biology to understand relapse and treatment resistance
This project will test whether combining clinical records with whole-genome and RNA sequencing plus blood tumor markers in people with multiple myeloma can reveal features that explain relapse and treatment resistance.
-
Multi-omics testing for blood and bone marrow cancers
This project will test a multi-omics lab approach on bone marrow, blood, biopsy and other fluid samples from people with suspected or known hematologic cancers to see if it can better characterize their disease.
-
e-Motion: Promoting Emotion Regulation for People Living with Chronic Cancer
This pilot tests two emotion-regulation programs—a guided self-help program and a combined group plus guided self-help program—for people recently diagnosed with metastatic or other chronic cancers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.